1-3 of 3
Surbhi Sidana
Close
Sort by
Journal Articles

Managing side effects: guidance for use of immunotherapies in multiple myeloma

Emily C. Liang, Surbhi Sidana
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2023) 2023 (1): 348–356.
https://doi.org/10.1182/hematology.2023000435
Published: 2023
Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.
https://doi.org/10.1182/hematology.2019000075
Published: 2019
Journal Articles

CAR T-cell therapy: is it prime time in myeloma?

Surbhi Sidana, Nina Shah
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 260–265.
https://doi.org/10.1182/hematology.2019000370
Published: 2019